Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.39 |
| ▸ | NAMPT | P43490 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4284348 | 0.90 | SMN1; SMN2 (0.44) | MAPTPOLBGRM4SMN1; SMN2ALDH1A1 | |
| SCHEMBL4287113 | 0.89 | MAPT (0.43) | MAPTPOLBGRM4SMN1; SMN2IRAK4 | |
| SCHEMBL4293881 | 0.89 | POLB (0.46) | MAPTPOLBGRM4SMN1; SMN2ALDH1A1 | |
| SCHEMBL4285697 | 0.87 | POLB (0.48) | MAPTPOLBGRM4SMN1; SMN2IRAK4 | |
| SCHEMBL4285473 | 0.87 | SMN1; SMN2 (0.45) | MAPTPOLBGRM4SMN1; SMN2ALDH1A1 | |
| SCHEMBL4285457 | 0.86 | POLB (0.41) | MAPTPOLBGRM4SMN1; SMN2IRAK4 | |
| SCHEMBL4290861 | 0.86 | MAPT (0.43) | MAPTPOLBGRM4SMN1; SMN2IRAK4 | |
| SCHEMBL4287327 | 0.85 | MAPT (0.42) | MAPTPOLBGRM4SMN1; SMN2IRAK4 | |
| SCHEMBL4285540 | 0.85 | NPC1 (0.43) | MAPTPOLBGRM4SMN1; SMN2ALDH1A1 | |
| SCHEMBL4294914 | 0.84 | POLB (0.43) | MAPTPOLBGRM4SMN1; SMN2IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1847531-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | GSK3B, GSK3A, GSKIP | MAPT 868/4885POLB 3501/4885GRM4 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.